I-Mab (NASDAQ:IMAB - Get Free Report)'s share price rose 0.6% during trading on Thursday . The stock traded as high as $0.86 and last traded at $0.84. Approximately 61,390 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 306,874 shares. The stock had previously closed at $0.84.
Analyst Upgrades and Downgrades
Separately, Brookline Capital Management upgraded I-Mab to a "strong-buy" rating in a research report on Thursday, February 27th.
Check Out Our Latest Research Report on IMAB
I-Mab Stock Performance
The stock's 50-day moving average is $0.94 and its two-hundred day moving average is $1.04.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. XTX Topco Ltd lifted its position in shares of I-Mab by 140.8% in the third quarter. XTX Topco Ltd now owns 43,039 shares of the company's stock worth $53,000 after buying an additional 25,163 shares in the last quarter. Millennium Management LLC raised its holdings in shares of I-Mab by 763.1% during the 4th quarter. Millennium Management LLC now owns 97,749 shares of the company's stock worth $83,000 after acquiring an additional 86,424 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of I-Mab during the 4th quarter valued at approximately $93,000. Cantor Fitzgerald L. P. purchased a new position in shares of I-Mab in the fourth quarter valued at $119,000. Finally, Garden State Investment Advisory Services LLC purchased a new position in shares of I-Mab in the third quarter valued at $179,000. Hedge funds and other institutional investors own 38.38% of the company's stock.
I-Mab Company Profile
(
Get Free Report)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.
Featured Stories
Before you consider I-Mab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and I-Mab wasn't on the list.
While I-Mab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.